

Remarks


The specification has been amended to clarify what the boxes in FIG. 1 represent.
Support can be found on page 32, line 21 - page 33, line 13.

Claims 14 and 15 have been added. Thus claims 1-15 are now pending. Support for new claims 14 and 15 can be found on page 26, lines 4-17 of the specification.

Therefore, no new matter is added by this amendment.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

09936655-091701

**Marked-up Version of Amended Claims and Specification
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)**

In the Specification on page 6, please replace the first paragraph under "Brief Description of the Figures" with the following:

Figure 1 is a graph that shows the results from assays that tested the resistance of transgenic potato tubers to soft rot. Discs prepared from tubers of *Desiree* control and transgenic plants expressing Demaseptin B (sample Nos. D1, D2, D6, D10) or Temporin A (sample Nos. T1, T2, T3) were infected with *E. carotovora* (black boxes) or left uninfected (white boxes). After 6 days at room temperature, rotted tissue was gently removed from the discs and the sensitivity/resistance to *E. carotovora* was expressed as the loss of weight of tuber tissue.

In the claims:

14. (New) The method of claim 13, wherein the cationic peptide is selected from the group consisting of the dermaseptins set forth in SEQ ID NOS: 3-14.

15. (New) The method of claim 13, wherein the cationic peptide is selected from the group consisting of the temporins set forth in SEQ ID NOS: 17-26.